Precision Decision Making in Platinum Resistant Ovarian Cancer: Folate Receptor Alpha Expression and Other Biomarkers Into Contemporary Care
Activity Overview
The GOG Foundation, Inc. and GOG Partners welcomes gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other clinicians who treat patients with gynecologic malignancies to join us for the Precision Decision‑Making in Platinum‑Resistant Ovarian Cancer: Folate Receptor Alpha Expression and Other Biomarkers Into Contemporary Care, an Educational Symposium being presented at the FSGO 2026 Annual Meeting in Long Boat Key, Florida a on Friday, June 12, 2026 from 7:35 am – 8:25 am ET.
This educational activity is supported by an independent medical education grant from AbbVie.
Course Description
Despite advances in ovarian cancer treatment, outcomes for patients with platinum‑resistant disease remains poor, with therapeutic decisions becoming increasingly complex as novel biomarkers and targeted therapies emerge. This 45‑minute case‑based educational program will provide clinicians with practical guidance on integrating folate receptor alpha (FRα) testing into real‑world decision‑making, alongside emerging considerations such as weekly paclitaxel and/or bevacizumab eligibility, PD-L1, HER2 status, and other biologic drivers. Through interactive discussion of patient cases led by two expert faculty, learners will explore how biomarker evaluation, clinical characteristics, and prior therapies influence treatment selection and sequencing, with an emphasis on optimizing outcomes in platinum‑resistant ovarian cancer.
Target Audience
Gynecologic and medical oncologists, oncology researchers, clinical trial investigators, advanced practice providers, and healthcare professionals involved in the care of patients with ovarian cancer.
Learning Objectives
Upon completion of the activities in this series, learners will be able to:
- Describe the clinical relevance of folate receptor alpha (FRα) expression in platinum‑resistant ovarian cancer and its role in identifying patients for targeted therapeutic approaches.
- Apply biomarker‑informed decision‑making—including FRα status, HER2 PD-L1 expression, and clinical eligibility for weekly paclitaxel and/or Bevacizumab to individualized treatment selection in platinum‑resistant disease.
- Evaluate real‑world patient cases to understand appropriate sequencing of therapies and integration of emerging evidence into contemporary management strategies.
Faculty
Scott Jordan, MD (Moderator)
Broward Health Medical Center
Bradley Monk, MD
Florida Cancer Specialists & Reserch Institute
Agenda
Precision Decision‑Making in Platinum‑Resistant Ovarian Cancer: Folate Receptor Alpha Expression and Other Biomarkers Into Contemporary Care, an Educational Symposium at the 2026 FSGO Annual Meeting.
This session is not included in the main event CME/CPD credit.
Scott Jordan, MD, Broward Health Medical Center
Bradley Monk, MD, Florida Cancer Specialists & Research Institute
All Faculty
All Faculty
All Faculty
Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.
The GOG Foundation, Inc. designates this internet live activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Declaration
In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.
Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.
All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.
NEW TERM *An “ineligible company” is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.